|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1989-12-18
|
|
pubmed:abstractText |
Plasma level, plasma clearance, production rate and interconversions of oestrone and oestrone sulphate were measured in six breast cancer patients receiving aminoglutethimide therapy. Three additional patients had the production rate of oestrone sulphate investigated. Plasma oestrone and oestrone sulphate levels were reduced by a mean of 46% (P less than 0.05) and 71% (P less than 0.005) respectively. These alterations were due to a combined action of aminoglutethimide inhibiting oestrogen production but also increasing oestrogen metabolism. While oestrone and oestrone sulphate production rate was reduced by a mean of 31% (P less than 0.05) and 41% (P less than 0.005) respectively, the plasma clearance rate of oestrone was found to be increased by a mean of 30% (P less than 0.05), and the plasma clearance rate of oestrone sulphate was increased by a mean of 112% during aminoglutethimide treatment. The fraction of oestrone sulphate converted into plasma oestrone was reduced by 52% (P less than 0.05), the transfer of circulating oestrone into sulphate was non-significantly reduced by a mean of 16%. The findings in this investigation show that aminoglutethimide treatment influences oestrogen disposition by mechanisms unrelated to aromatase inhibition. The possibility that such effects might be partly responsible for the mechanism of action of aminoglutethimide in advanced breast cancer should be considered.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-1164821,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-14084134,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-263348,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-2933050,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-3048976,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-3436111,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-3595668,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-3719899,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-3830220,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-4370479,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-4688315,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-4820661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-5008222,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-568029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-5764540,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-5822587,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6099033,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6221177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6222901,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6233150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6499359,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6652931,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-6740741,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-679502,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-7078905,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-7198170,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-7376217,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-837338,
http://linkedlifedata.com/resource/pubmed/commentcorrection/2553085-903399
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
107-11
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
1989
|
|
pubmed:articleTitle |
Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide.
|
|
pubmed:affiliation |
Department of Therapeutic Oncology and Radiophysics, University of Bergen, Norway.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
